Champions Oncology to Present Eight Studies at AACR 2026
Champions Oncology said it will present eight poster presentations at AACR 2026 in San Diego on April 17-22. The studies cover KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, ADCs and CAR-T therapies.
Champions Oncology, Inc. said it will present new data across eight poster presentations at the 2026 American Association for Cancer Research Annual Meeting, taking place April 17-22, 2026, in San Diego, California. The studies are intended to show how clinically relevant models and integrated data can reduce translational risk and guide development decisions.
The presentations will highlight research across key areas of oncology drug development, including KRAS-mutant tumors, ovarian cancer, glioblastoma, radiopharmaceuticals, antibody-drug conjugates, and CAR-T therapies. The company said the data focus on helping biopharma partners understand therapeutic response and resistance, identify actionable biomarkers, and make more informed development decisions earlier in the pipeline.
Using clinically relevant, patient-derived models together with integrated molecular, functional, and phenotypic data, the studies demonstrate how translationally relevant preclinical approaches can improve prediction, reduce development risk, and strengthen the connection between tumor biology and clinical strategy.
The company said its scientists will be available throughout AACR 2026 to discuss study design, analytical approaches, and collaboration opportunities.